research TRAPPED IN THE HYPOGLYCEMIA LOOP
Early advanced therapies are crucial for better survival in aggressive insulinoma cases.
Search
for
Sort by
Research
780-810 / 1000+ resultsresearch Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?
Topical rapamycin may effectively treat fibrous papules on the face.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
research High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
CD8+ T cells are involved in alopecia areata and may cause disease relapse.
research Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation
Overexpression of HDGF in melanocytes does not cause cancer.
research Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
research SIDE EFFECTS OF CYCLOSPORINE COMPARED TO TACROLIMUS AMONG YEMENI KIDNEY TRANSPLANT PATIENTS WHO SHARE THE SAME ADJUVANT AGENTS: MYCOPHENOLATE MOFETIL AND PREDNISONE
Tacrolimus is a better option than cyclosporine due to fewer side effects.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Sometimes Marketing Efforts by Advocacy Organizations Can Lose Touch with the Nuances of Appropriateness
Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
research Increased Expression of TSPEAR in Colorectal Cancer Predicts Poor Prognosis
High TSPEAR levels in colorectal cancer predict worse outcomes.
research Characters of KRT80 and its roles in neoplasms diseases
KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.
research Abiraterone and spironolactone in prostate cancer: a combination to avoid
Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Eyelash trichomegaly complicating pembrolizumab for colorectal cancer
Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
research “Arrow” sign: A rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors
A new method quickly detects hair changes from EGFR inhibitors using a microscope.
research Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Skin reactions from cancer treatments might predict how well the treatments work.
research Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis
Topical tofacitinib may help regrow hair in children with alopecia totalis.
research Increased Expression of TSPEAR in Colorectal Cancer Predicts Poor Prognosis
High TSPEAR levels in colorectal cancer predict worse outcomes.
research Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice.
Lack of KSR1 stops certain skin tumors in mice.
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Repigmentation of hair following adalimumab therapy
A patient's grey hair regained color during treatment with adalimumab.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Alopecia universalis unter Adalimumabtherapie bei einer Patientin mit rheumatoider Arthritis
A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Loose anchoring of anagen hairs and pili torti due to erlotinib
Erlotinib can cause hair loss and texture changes.
research S100A8 induces cyclophosphamide-induced alopecia via NCF2/NOX2-mediated ferroptosis
Blocking S100A8 can reduce chemotherapy-induced hair loss.